More Than 20 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 58th Annual ASH Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi ® (ruxolitinib) and its small molecule development programs targeting JAK1, LSD1 and PI3Kd will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2016 in San Diego, California from December 3-6, 2016.

"We are pleased to have an array of data highlighting the potential of our portfolio accepted for presentation at this year's ASH meeting, including the pooled overall survival analysis of five-year data from our COMFORT-I and COMFORT-II trials, which reinforces the long-term clinical profile of Jakafi; data from INCB39110, our selective JAK1 inhibitor, in acute graft-versus-host disease; and emerging data from our LSD1 and PI3Kd inhibitor programs in other hematologic diseases," said Steven Stein, M.D., Incyte's Chief Medical Officer.

Key abstract presentations and publications, inclusive of studies sponsored by Incyte, Novartis and independent investigator studies, include:
 

Myelofibrosis

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients (pts) with Myelofibrosis (MF) Enrolled in the COMFORT-I Study (Abstract #1949)
 

• Saturday, December 3, 2016, 5:30-7:30 PM PST, Hall GH, Poster Session: 634
 

Ruxolitinib (RUX) plus Pomalidomide in Myelofibrosis (MF): Updated Results from the MPNSG-0212 Trial (NCT01644110) (Abstract #1939)

• Saturday, December 3, 2016, 5:30-7:30 PM PST, Hall GH, Poster Session: 634
 

Clinical Outcomes with Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) Stratified by Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials (Abstract #3118)

• Sunday, December 4, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

A Pooled Overall Survival Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib (RUX) for the Treatment of Myelofibrosis (MF) (Abstract #3110)

• Sunday, December 4, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

Safety and Efficacy of Ruxolitinib (RUX) for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients (pts) with Myelofibrosis (MF) (N = 2233) (Abstract #3107)

• Sunday, December 4, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) as Therapy for Patients (pts) with Myelofibrosis (MF) (Abstract #1127)

• Monday, December 5, 2016, 4:30-6:00 PM PST, Ballroom Salons 15-17, Oral Presentation: 634
 

Exploring the potential of JAK1/2 inhibitor Ruxolitinib (RUX) with reduced intensity hematopoietic cell transplantation (HCT) for Myelofibrosis (MF): Stage I results of a prospective trial conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC) (Abstract #1126)

• Monday, December 5, 2016, 4:30-6:00 PM PST, Pacific Ballroom Salons 15-17, Oral Presentation: 634
 

Polycythemia Vera

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study (Abstract #1934)

• Saturday, December 3, 2016, 5:30-7:30 PM PST, Hall GH, Poster Session: 634
 

Essential Thrombocythemia

Correlation between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the MAJIC Study which compared Ruxolitinib (RUX) to Best Available Therapy in Essential Thrombocythemia (ET) (Abstract #1929)

• Saturday, December 3, 2016, 5:30-7:30 PM PST, Hall GH, Poster Session: 634
 

Myeloproliferative Neoplasms

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey (Abstract #4265)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

The impact of Myeloproliferative Neoplasms (MPNs) on patients' quality of life and productivity: Results from the international MPN LANDMARK survey (Abstract #4267)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

Other Hematologic Malignancies

A Phase I Study of Ruxolitinib (RUX) Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease (Abstract #1892)

• Saturday, December 3, 2016, 5:30-7:30 PM PST, Hall GH, Poster Session: 632
 

A Phase 1 Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD) (Abstract #390)

• Sunday, December 4, 2016, 12:00-1:30 PM PST, Grand Hall C, Oral Presentation: 722
 

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease (Abstract #2472)

• Sunday, December 4, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 113
 

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo (Abstract #3297)

• Sunday, December 4, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 652
 

Safety and efficacy of combined Ruxolitinib (RUX) and Decitabine in patients with blast-phase MPN and post-MPN AML: Results of a Phase I study (Myeloproliferative Diseases Research Consortium 109 trial) (Abstract #1124)

• Monday, December 5, 2016, 4:30-6:00 PM PST, Pacific Ballroom Salons 15-17, Oral Presentation: 634
 

An ongoing open-label phase 1/2 study of INCB050465, a selective PI3Kd inhibitor, in patients with previously treated B-cell malignancies (Abstract #4195)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 626
 

Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) (Abstract #4246)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

Phase I Study of Ruxolitinib (RUX) for Patients (pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy (Abstract #4318)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 637
 

Phase I/II study of Ruxolitinib (RUX) with decitabine (DAC) in patients with post-myelofibrosis neoplasm acute myeloid leukemia (post-MPN AML): Phase I results (Abstract #4262)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 634
 

A LYSA phase II study of oral JAK1/2 inhibitor Ruxolitinib in advanced relapsed/refractory (R/R) Hodgkin lymphoma (HL) (Abstract #4160)

• Monday, December 5, 2016, 6:00-8:00 PM PST, Hall GH, Poster Session: 624

 

Full sessions details and data presentation listing for ASH 2016 can be found at: http://www.hematology.org/Annual-Meeting/Abstracts/2853.aspx

About Jakafi ® (ruxolitinib)

Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration, for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)